The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Abstract

Background Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories. Methods We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the basis of hospital and claims data. Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost due to premature death and years lived with disability. Estimates are presented as numbers and age-standardised or age-specific rates per 100 000 population, with 95% uncertainty intervals (UIs). All estimates are presented for five causes of cirrhosis: hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis (NASH), and other causes. We compared mortality, prevalence, and DALY estimates with those expected according to the Socio-demographic Index (SDI) as a proxy for the development status of regions and countries. Findings In 2017, cirrhosis caused more than 1•32 million (95% UI 1•27-1•45) deaths (440 000 [416 000-518 000; 33•3%] in females and 883 000 [838 000-967 000; 66•7%] in males) globally, compared with less than 899 000 (829 000-948 000) deaths in 1990. Deaths due to cirrhosis constituted 2•4% (2•3-2•6) of total deaths globally in 2017 compared with 1•9% (1•8-2•0) in 1990. Despite an increase in the number of deaths, the age-standardised death rate decreased from 21•0 (19•2-22•3) per 100 000 population in 1990 to 16•5 (15•8-18•1) per 100 000 population in 2017. Sub-Saharan Africa had the highest age-standardised death rate among GBD super-regions for all years of the study period (32•2 [25•8-38•6] deaths per 100 000 population in 2017), and the high-income super-region had the lowest (10•1 [9•8-10•5] deaths per 100 000 population in 2017). The age-standardised death rate decreased or remained constant from 1990 to 2017 in all GBD regions except eastern Europe and central Asia, where the age-standardised death rate increased, primarily due to increases in alcohol-related liver disease prevalence. At the national level, the age-standardised death rate of cirrhosis was lowest in Singapore in 2017 (3•7 [3•3-4•0] per 100 000 in 2017) and highest in Egypt in all years since 1990 (103•3 [64•4-133•4] per 100 000 in 2017). There were 10•6 million (10•3-10•9) prevalent cases of decompensated cirrhosis and 112 million (107-119) prevalent cases of compensated cirrhosis globally in 2017. There was a significant increase in age-standardised prevalence rate of decompensated cirrhosis between 1990 and 2017. Cirrhosis caused by NASH had a steady age-standardised death rate throughout the study period, whereas the ot...

Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?

“…From 1990 to 2017 cirrhosis-caused deaths increased from less than 900,000 to more than 1.32 million per year globally. Importantly, the prevalence of cirrhosis caused by NASH increased more than any other cause in that period of time [ 9 ].…”

Nuclear deformation mediates liver cell mechanosensing in cirrhosis

“…With 844 million cases and 2 million deaths per year, chronic liver disease represents 1 of the major public health problems worldwide. 22,23 As morbidity and mortality mostly concern patients with ACLD, there is a need for therapeutic strategies aiming at improving the disease in this late stage. 24 Mechanical forces, including ECM stiffness or mechanical stretch, can regulate the cellular phenotype.…”

Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study

“…Health Data Exchange (GHDx) online database; the annual HCC incidence from WHO CI5plus/IARC 2010-2012, WHO Globocan 2018, Polaris online database; the annual HBV-related death with WHO Globocan 2018 online database; the annual LT incidence from the China Liver Transplant Registry (CLTR) online database [32][33][34][35][36]; the annual number of cirrhosis deaths from published global disease burden studies [37,38]; and the total chronic HBV infection prevalence from studies published by Chinese hepatology experts for the base case scenario [22]. In addition, in the natural history scenario, we compared our predicted cumulative 10-year probabilities of HBsAg loss and chronic hepatitis with those in published studies on inactive carriers [39] (Supplementary S 1.5).…”